Background-Outcomes of ventricular tachycardia (VT) ablation have been described in clinical trials and single-center studies. We assessed the safety of VT ablation in clinical practice. 
V entricular tachycardia (VT) ablation is now performed throughout the United States in both community and tertiary medical centers, and use of this procedure has increased during the past decade. 1, 2 Previous studies suggest that patients without structural heart disease experience greater procedural success and fewer periprocedural complications, [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] but little more is known about the factors that predispose patients to complications. Although a recent observational study assessed the incidence of complications in patients with postinfarct VT ablation, 1 the vast majority of literature addressing complications of VT ablation come from randomized trials or high-volume single-center retrospective studies. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] With their small sample sizes and relatively low absolute numbers of adverse events (AEs), these publications preclude conclusions about clinical and institutional characteristics associated with periprocedural AEs or changes in event rates over time. Using publicly available hospital discharge data from multiple states in the United States, we assessed the frequency with which in-hospital AEs occurred in association with VT ablation. We sought to characterize patient-and systems-level characteristics associated with in-hospital adverse outcomes and trends in patient characteristics and outcomes over time. (2003) (2004) (2005) (2006) (2007) , 21 and New Jersey (1997-2011). 22 We included all hospital encountering with an endovascular cardiac ablation (International Classification of Diseases-9 [ICD-9] Clinical Modification [CM] code: 37.34) and a primary discharge diagnosis of VT (ICD-9 CM code: 427.1). 1, 23 All other hospital records were excluded. All ICD-9 CM codes used in this analysis are found in the table in the Data Supplement.
The primary outcome for this study was any in-hospital periprocedural AE defined as death, stroke, intracerebral hemorrhage, pericardial complications defined as pericarditis, hemopericardium, tamponade, or pericardiocentesis, postprocedural hematoma, hemorrhage or cardiac complications, blood transfusion, or cardiogenic shock. These diagnoses were chosen because they were considered much more likely to be procedural complications than other potential complications that may present concomitantly with VT, such as worsening heart failure (HF), respiratory failure, or heart block. Secondary outcomes included in-hospital death and a composite outcome of major AEs (MAEs), including cardiogenic shock, in-hospital death, stroke, intracerebral hemorrhage, and cardiac tamponade or need for pericardiocentesis.
Baseline patient characteristics, including the route of admission, were determined using data-set documentation. Patients were classified as having HF and coronary artery disease (CAD), HF without CAD, congenital heart disease, or no structural heart disease. Use of electroanatomical mapping (ICD-9 CM procedure code 37.27) was also determined. Annual volume of VT ablations by hospital was quantified to determine the relationship between hospital procedure volume and AEs. Regional trends in the average number of cases per center and AE were also determined.
Statistical Analysis
Associations between primary and secondary outcomes and baseline demographics, comorbidities, route of admission, year of hospitalization, and region were modeled using a multivariable mixed effects model with random effects terms for state and hospital using forward selection. All patient characteristics with a χ 2 P value of <0.05 between patients with no event and with an event were included in the univariate mixed effects binomial regression models for each outcome. An entry criterion of P<0.05 in univariate analysis was used for multivariable analysis. Harmonization of demographics, in-hospital outcomes, diagnosis, and procedure codes was performed using MySQL Server (version 5.5.24). All statistical analyses were performed using the R statistical package (version 3.1.1; R Foundation for Statistical Computing, Vienna, Austria). Specifically, the glmer function in the lme4 package was used to apply univariate and multivariable mixed effects models using a binomial distribution for all outcomes. Deidentification procedures in CA resulted in large numbers of hospitalizations with missing data on age, race, and sex. A sensitivity analysis was performed using data only from the state of New York and NJ, which reported virtually no missing demographic data (0% age, 0% sex, and 7.9% race missing), to confirm the findings of the primary analysis. The annual incident rate for 
WHAT IS KNOWN
• Reports on adverse events (AEs) associated with ventricular tachycardia ablation vary widely, but complications are generally more common in the presence of structural heart disease.
WHAT THE STUDY ADDS
• An understanding of the incidence of AEs associated with ventricular tachycardia ablation generally (8.5%) and for patients with structural heart disease (14.7%) and major adverse event rates in these populations.
• Evidence that both the number of risk factors for AEs and incidence of AEs are increasing over time.
• Further demonstration that high procedural volume is associated with fewer AEs. the number of risk factors (RFs) per patient was calculated using a mixed effects Poisson regression model. Outcome trends were adjusted according to the presence of RFs on an individual hospitalization basis using multivariable mixed effects binomial regression models. Volume-outcome analyses were conducted using logistic regression (glm function) because of the inclusion of the hospital-specific volume term in the predictive model. Relationships between annual VT ablation volumes of <10, 10 to 25, and >25 were quantified on the basis of recently published data, suggesting a relationship between these VT ablation volumes and in-hospital complications. 1 Data about proceduralist volume were not available.
Results
Of 116 350 103 hospitalizations from the combined data sources, there were 150 520 hospitalizations (1.3%) with a primary diagnosis of VT of which 9699 (0.008% of all hospitalizations; 6.4% of hospitalizations with a primary diagnosis of VT) reported intracardiac ablation. Baseline characteristics of patients are summarized in Table 1 . Data on age, sex, and race were not available in 19.6%, 19.1%, and 27.6% of hospitalizations, respectively, because of state-specific deidentification procedures. Excluding hospitalizations with missing data, the overall demographics of VT ablation hospitalizations reported predominantly white race (n=4827; 69.3%; 2734 missing), male sex (n=4716; 60.1%; 1851 missing), and age >50 years (n=5533; 67.2%; 1462 missing).
Of the 9699 hospitalizations with VT ablation, 825 (8.5%) were associated with in-hospital AEs, 295 (36.1% of AEs; 3.0% of hospitalizations) of which were MAEs. Death occurred in 110 (1.1%) hospitalizations. More than 1 AE was reported in 259 (2.7%) hospitalizations, and >1 MAE was reported in 63 (0.6%). Need for blood transfusion was the most common AE associated with VT ablation, occurring in 224 (2.3%) hospitalizations. In χ 2 analysis, age ≥60 years and male sex were associated with higher rates of AEs of any sort, as were structural heart disease (congenital heart disease or HF±CAD), diabetes mellitus, and atrial fibrillation. The majority of ablations were performed during hospitalizations of patients without structural heart disease (6635 total;68% of hospitalizations) with event rates of 5.6% for any AE, 1.4% for MAE, and 0.3% for in-hospital death. Ablation performed during hospitalization of patients with structural heart disease was associated with event rates of 453 (14.7%) for AE, 198 (6.5%) for MAE, and 31 (3.0%) for in-hospital death (P<0.001 for all compared with no structural heart disease). Patients with HF, but no CAD (n=1392, 14.4%), had gross event rates of 173 (12.4%), 86 (6.2%), and 40 (2.9%) for AE, MAE, and in-hospital death, respectively, whereas patients with both HF and CAD (n=1518; 15.7%) had gross rates of 268 (17.7%), 109 (7.2%), and 51 (3.4%). The rate of AEs was significantly greater in HF patients with CAD versus no CAD (P<0.001), but rates of MAE and death were not significantly different. Rates of periprocedural AE and MAE increased over time as depicted in Figure 1 . Likelihood of in-hospital AEs increased by an odds ratio (OR) of 1.04 (95% confidence interval [CI], 1.00-1.07) per year (P<0.05), and MAEs increased by an OR of 1.07 (95% CI, 1.01-1.4) per year (P<0.001). Odds of in-hospital mortality did not increase significantly over time (P=0.86).
Advancing age, HF±CAD, anemia, atrial fibrillation, and admission via transfer or the emergency department (ED) remained independent predictors of AEs, MAEs, and death in multivariable analysis as demonstrated in Tables 2 to 4 . HF without CAD had the strongest association with death 
Route of Admission
Patients admitted directly from home accounted for 5682 (58.6%) of all hospitalizations considered in the analysis, whereas admissions via the ED or by hospital transfer made up 2015 (20.8%) and 1977 (20.4%) of records analyzed, respectively. Characteristics of patients admitted by each of these 3 mechanisms are described in Table 5 . Patients admitted from home were less likely to have structural heart disease, diabetes mellitus, anemia, or atrial fibrillation (P<0.01 for all). Excluding the RF of admission source, patients admitted via the ED or by hospital transfer had a higher average number of RFs when compared with patients admitted from home (1.14, 1.18, and 0.74 RFs per patient, respectively, P<0.001). Patients admitted via the ED were more likely than patients admitted 
Hospital Ablation Volume
Hospital volume was defined as the average annual volume for all years that each hospital reported performing ≥1 ablation. In total, 200 unique hospitals reported performing VT ablation during the study period with a cumulative median of 4 cases/y. The median for average procedural volume was 2.9 cases/y (interquartile range, 1.5 to 5.8; the majority of procedures 7047 (72.7) were performed in hospitals of the highest volume quartile (>5.8 procedures annually on average). (7) 30-39 138 (7) 96 (5) 511 (9) 40-49 276 (14) 188 (10) 811 (14) 50-59 342 (17) 295 (15) (3) 14 (1) 18-29 253 (5) 200 (6) 52 (5) 30-39 359 (7) 283 (8) 103 (9) 40-49 670 (13) 460 (13) 146 (13) 50-59 863 (17) 528 (15) 177 (16) 60-69 964 (19) 610 (17) 207 (19) >70 1281 (25) 696 (20) 225 (20) NA 645 (13) 624 (18) 194 (17 (14) 324 (9) 52 (5) Hispanic 305 (6) 163 (5) 70 (6) Other race 224 (4) 245 (7) 50 (4) NA 1415 (28) 1074 (31) 245 (22) Structural heart disease 0.003 Significant differences in the AE rate were also observed between hospitals with <10 (n=448; 8.8%), 10 to 25 (n=305; 8.7%), and >25 (n=72; 6.4%) hospitalizations for VT ablation/y (χ 2 P=0.03), but there were no significant differences in rates of MAE or in-hospital death. The difference in AEs was driven by high-volume hospitals with >25 hospitalizations/y who reported a significantly lower overall unadjusted AE rate (6.4% versus 8.8% versus all other hospitals; OR, 0.72; 95% CI, 0.56-0.92; P=0.008), although only 3 hospitals in the 6 states had average annual volumes of >25 procedures per year.
Hospital volume >25 cases/y also remained significantly associated with a lower rate of AE when adjusted for the number of AE RFs (OR, 0.72; 95% CI, 0.56-0.93; P=0.013). There was no association between hospital volume and MAE (P=0.36) or in-hospital death rates.
There was a small, homogeneous increase in the mean number of VT ablations per center in the 3 highest volume states (New York, CA, and NJ) between the years 1994 and 2007 with a subsequent abrupt increase in the number of cases per center in NJ from 2007 to 2011 (Figure 2 ). Despite these modest increases in hospital volumes, ablation-associated AEs increased at similar rates across all 3 states with the exception of the past 4 years when AE rates in New Jersey and California appeared to diverge in association with an increase in the number of cases per center in New Jersey compared with California. When the average number of cases per center by state was included in a multivariable logistic regression model along with the year of hospitalization, the number of high-risk features, and the state, an increase of 1 case per center was associated with lower odds of AE (OR, 0.94; 95% CI, 0.90-0.98; P=0.003), but there were no significant differences in MAE (P=0.21) or mortality (P=0.38).
Trends in AEs and Patient Complexity
The percentage of patients with ≥2 RFs (high risk) for AEs also increased throughout the period studied from 15.6% to 39.9% (Figure 3) . This corresponded to a Poisson regression incident rate of 1.025 (95% CI, 1.02-1.03; P<0.001) annually. The increase in percentage of patients who were high risk was the greatest among patients admitted from home (6.5%-34.8%; incident rate, 1.057; 95% CI, 1.04-1.08; P<0.001), although the annual increase in percentage of high-risk patients was also significant for transfer patients (26.3%-51.2%; incident rate, 1.01; 95% CI, 1.00-1.02; P=0.006). The percentage of ED patients with ≥2 RFs was more variable but did increased overall during the study period (incident rate, 1.01; 95% 
Discussion
Over a 19-year period, ≈8.5% of VT ablations were associated with AEs, including MAEs in 3% of procedure-related hospitalizations with higher rates of complications, including in-hospital death observed in patients with structural heart disease. These rates are within the range reported in most single-center studies and randomized controlled trials of VT ablation, although rates in these publications vary widely. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] 24 In particular, the overall MAE rate reported in this study for patients with structural heart disease (6.2%) is similar to the rate of 6.0% in the most recent report from Brigham and Women's Hospital where ≈370 VT ablations were performed over a 2-year period 14 and lower than was observed in the largest multicenter trial of VT ablation. 24 In comparison with a recent report using data from the National Inpatient Survey examining patients undergoing ablation for postinfarct VT, we found higher AE and in-hospital death rates (17.6% versus 11.2% and 3.3% versus 1.6%) (24) , but MAE and in-hospital death rates were similar to those seen in clinical trials of ablation for recurrent VT with predominantly ischemic heart disease. 1, 4, 24 Overall, the odds of death among HF patients with or without CAD were significantly elevated when compared with odds of death in patients without structural heart disease but statistically similar to one another. In patients without structural heart disease, MAE rates were lower than that reported from Brigham and Women's Hospital and in a Spanish registry (1.4% versus 3.4% versus 3.4%), although the occurrence of in-hospital death was higher (0.3% versus 0% versus 0%). 2, 14 We found an association between periprocedural AEs, advancing age, and the presence structural heart disease with or without CAD in hospitalized patients undergoing VT ablation. These findings refute previous publications that advanced age is not associated with higher AE rates 11, 25 but support findings that structural heart disease is associated with higher rates of complications. 1, 4, 8, 14, 24, 26 Interestingly, in contrast to published data on outcomes in acute coronary syndromes and catheterization, which demonstrate higher AE rates in women when compared with men, 27, 28 we found that female sex was associated with fewer AEs after VT ablation.
Although adverse outcomes associated with VT ablation have increased over time, our data demonstrate concomitant increase in patient RFs, which may explain part but not all of the observed trends in AEs. The observed trend of increasing RFs in patients suggests that sicker patients are undergoing ablation, particularly those admitted from home who are undergoing elective ablation. Increased success rates and operator competence may contribute to this trend, although a different data source would be required to assess for procedural success. Furthermore, improved procedural technique and technologies have the potential to offset some of the risks inherent to ablating sicker patients. Our data demonstrate the increased use of electroanatomic mapping over time, but selection bias precludes the assessment of mapping's effect on AE rates.
Other surgical specialties have decreased complication rates by further concentrating higher-risk procedures in highvolume centers. For instance in Germany, minimum volume requirements for total knee replacement resulted in 22.5% and 44% risk reductions in wound infections and bleeding complications, respectively. 29 Within electrophysiology, lower complication rates have recently been reported in higher volume device implantation centers and among higher volume operators for device implantation and atrial fibrillation ablation. 23, 30, 31 Whether concentrating ablation volume to select centers is a practical approach to decreasing complication rates in VT ablation is not clear. Unlike the aforementioned elective procedures, VT ablation may be done urgently and emergently. In fact, we demonstrate that, in lower volume ablation centers, patients undergoing ablation were more likely to have been admitted via the ED than patients ablated at higher volume centers. AE rates were also higher in lower volume centers, although it is unclear how much of this difference was attributable to patient selection and how much to provider or center proficiency. Although there may be certain circumstances in which concentrating VT ablation in high-volume centers is challenging, Della Bella et al 32 have described a VT unit able to provide helicopter accessible, around-the-clock intensive care management by a team that included multiple electrophysiologists working in co-operation with HF specialists and cardiac surgeons. 32 Although our data suggest that patient transfer is not associated with lower complication rates than those observed in patients admitted via the ED, not all patients were transferred to hospitals in the highest volume quartile and not all hospitals in the highest volume quartile may truly qualify as high-volume VT ablation centers. Our data do suggest that the highest volume hospitals, defined here as those performing >25 procedures per year on average, do have lower complication rates, suggesting that further concentration of VT ablation as suggested by Della Bella et al 32 
Limitations
This study is subject to limitations inherent to all claimsbased studies, including unidentified confounders, misclassification, and missing data because of state administrative procedures for deidentification. The lack of granularity in administrative data prevents assessment of important clinical and procedural characteristics, including VT mechanism and substrate (idiopathic versus scar-related), cardiac site of the VT origin, left ventricular ejection fraction, and procedural equipment, as well as limiting comparison with clinical trials and registries. Although patients admitted for premature ventricular complex ablation have had a different ICD-9 CM code than those admitted with a primary diagnosis of VT, we can neither differentiate between nonsustained VT and sustained or hemodynamically significant VT in this analysis nor can we exclude the possibility that patients undergoing ablation of premature ventricular complexes were included in the analysis. Data on the presence of chronic renal insufficiency were lacking because of a change in the ICD-9 CM codes during the study period. Discharge data sets do not allow for the assessment of individual provider volume, which may better predict procedural outcomes than does institutional volume. Deidentified hospital discharge data also do not permit for the assessment of AEs in patients presenting for >1 VT ablation on a per-patient basis. Events reported here are assumed to be directly related to the ablation procedure but may be overestimates as causality cannot be proven. In addition, nonspecific conditions, such as worsening HF or respiratory failure, that might be procedural complications but could also be attributable to underlying comorbidities were excluded, potentially underestimating true AE rates. Finally, procedural success cannot be ascertained from these data, and so the balance of risks and benefits provided by VT ablation cannot be assessed.
Conclusions
Using a multistate hospital discharge database, we found that AEs occurred in 8.5% of hospitalization during which ablation of VT was performed. Major AEs, including death, occurred in 3% of hospitalizations. Event rates in patients with and without structural heart disease were similar to those reported from high-volume centers and in randomized controlled trials. HF, anemia, increasing age, male sex, and hospital admission via the ED were the traits most strongly associated with inhospital AEs. Gross rates of AEs increased slightly over time, as did the average per-patient number of RFs. Fewer AEs were seen at higher volume centers.
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